Drug General Information
Drug ID	D0V5KW
Former ID	DIB007563
Drug Name	EZN-2279
Synonyms	PEG-rADA; PEGylated recombinant adenosine deaminase (SCID), Sigma-Tau
Indication	Immunodeficiency [ICD9: 279.3; ICD10:D84.9]		Phase 3	[523593]
Company	Enzon Pharmaceuticals Inc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Adenosine deaminase	Target Info	Modulator	[551689]
BioCyc Pathway	Purine nucleotides degradation
	Purine deoxyribonucleosides degradation
	Purine ribonucleosides degradation to ribose-1-phosphate
	Adenosine nucleotides degradation
	Superpathway of purine nucleotide salvage
	Adenine and adenosine salvage III
KEGG Pathway	Purine metabolism
	Metabolic pathways
	Primary immunodeficiency
NetPath Pathway	TCR Signaling Pathway
	IL2 Signaling Pathway
PANTHER Pathway	Adenine and hypoxanthine salvage pathway
Pathway Interaction Database	p73 transcription factor network
	C-MYB transcription factor network
	Validated transcriptional targets of deltaNp63 isoforms
	Validated transcriptional targets of TAp63 isoforms
PathWhiz Pathway	Purine Metabolism
Reactome	Purine salvage
WikiPathways	Metabolism of nucleotides
References
Ref 523593	ClinicalTrials.gov (NCT01420627) EZN-2279 in Patients With ADA-SCID. U.S. National Institutes of Health.
Ref 551689	Clinical pipeline report, company report or official report of Sigma-Tau Pharmaceuticals, Inc.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.